Company Overview and News
TORONTO, April 18, 2018 (GLOBE NEWSWIRE) -- Denison Mines Corp. (“Denison” or the “Company”) (TSX:DML) (NYSE MKT:DNN) (NYSE American:DNN) is pleased to report the discovery of high-grade uranium mineralization 600 metres and 1 kilometre to the northeast of the Gryphon uranium deposit, on the Company’s 63.3% owned Wheeler River project, in northern Saskatchewan. The winter drilling program is now complete, resulting in a total of 21,153 metres drilled in 29 diamond drill holes.
DNN U CCJ DML URPTF
TORONTO, April 05, 2018 (GLOBE NEWSWIRE) -- Uranium Participation Corporation ("UPC" or the “Corporation”) today filed its Financial Statements and Management's Discussion & Analysis ("MD&A") for the year ended February 28, 2018. Both documents can be found on the Company's website (www.uraniumparticipation.com) or on SEDAR (www.sedar.com). The highlights provided below are derived from these documents and should be read in conjunction with them.
U CCJ URPTF
TORONTO, April 04, 2018 (GLOBE NEWSWIRE) -- Uranium Participation Corporation ("UPC”) (TSX:U) reports its estimated net asset value at March 31, 2018 was CAD$462.3 million or CAD$3.49 per share. As at March 31, 2018, UPC’s uranium investment portfolio consisted of the following:
TORONTO, March 28, 2018 (GLOBE NEWSWIRE) -- Denison Mines Corp. (“Denison” or the “Company”) (TSX:DML) (NYSE American:DNN) is pleased to announce that it has filed its 2017 annual report on Form 40-F with the U.S. Securities and Exchange Commission ("SEC"). Denison’s Form 40-F incorporates by reference the management discussion and analysis and audited financial statements of the Corporation for the year ended December 31, 2017, as furnished to the Commission on Denison’s Form 6-K dated March 9, 2018.
DNN U DML URPTF
TORONTO, March 27, 2018 (GLOBE NEWSWIRE) -- Denison Mines Corp. (“Denison” or the “Company”) (TSX:DML) (NYSE MKT:DNN) (NYSE American:DNN) is pleased to announce an increase in the mineral resources estimated for the Midwest Project, located in the eastern Athabasca Basin, northern Saskatchewan, Canada. The Project is host to the high-grade Midwest Main and Midwest A uranium deposits which lie along strike and within six kilometres of the J Zone deposit and Huskie discovery on Denison’s 64.
DNN U DML URPTF
2018-03-16 marketwired - 2
TORONTO, ONTARIO--(Marketwired - March 16, 2018) - Denison Mines Corp. ("Denison" or the "Company") (TSX:DML)(NYSE MKT:DNN)(NYSE American:DNN) today announces that it filed a technical report under Canadian Securities Administrators' National Instrument 43-101 Standard of Disclosure for Mineral Projects for its 63.3% owned Wheeler River Project in Saskatchewan titled "Technical Report with an Updated Mineral Resource Estimate for the Wheeler River Property, Northern Saskatchewan, Canada" dated March 15, 2018 with an effective date of March 9, 2018.
DNN U DML URPTF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSX:U / Uranium Participation Co on message board site Silicon Investor.